Braden Corbin

Braden Corbin

Auto-generated profile, based on publicly available information

Braden Corbin

Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2018 in JCI Insight
Verified
Journal Article
Open access
PDF file
MCMarta Christov
Marta Christov
ACAbbe R. Clark
Abbe R. Clark
BCBraden Corbin
Braden Corbin
SHSamy Hakroush
Samy Hakroush
EREugene P. Rhee
Eugene P. Rhee
AGAnna Greka
Anna Greka
Progressive chronic kidney diseases (CKDs) are on the rise worldwide. However, the sequence of events resulting in CKD progression remain poorly understood. Animal models of CKD exploring these issues are confounded by systemic toxicities or surgical interventions to acutely induce kidney injury. Here we report the generation of a CKD mouse model through the inducible podocyte-specific ablation of an essential endogenous molecule, the chromatin structure regulator CCCTC-binding factor (CTCF), which leads to rapid podocyte loss (iCTCF pod–/– ). As a consequence, iCTCF pod–/– mice develop severe progressive albuminuria, hyperlipidemia, hypoalbuminemia, and impairment of renal function, and die within 8–10 weeks. CKD progression in iCTCF pod–/– mice leads to high serum phosphate and elevations in fibroblast growth factor 23 (FGF23) and parathyroid hormone that rapidly cause bone mineralization defects, increased bone resorption, and bone loss. Dissection of the timeline leading to glomerular pathology in this CKD model led to the surprising observation that podocyte ablation and the resulting glomerular filter destruction is sufficient to drive progressive CKD and osteodystrophy in the absence of interstitial fibrosis. This work introduces an animal model with significant advantages for the study of CKD progression, and it highlights the need for podocyte-protective strategies for future kidney therapeutics.